» Articles » PMID: 12471610

Current Status of the Molecular Genetics of Human Prostatic Adenocarcinomas

Overview
Journal Int J Cancer
Specialty Oncology
Date 2002 Dec 10
PMID 12471610
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Molecular genetic mechanisms involved in the progression of prostate cancer are not well understood due to extensive tumor heterogeneity and lack of suitable models. New methods such as fluorescence in-situ hybridization (FISH), comparative genomic hybridization (CGH) and microsatellite analysis have documented losses or gains on various chromosomes. Altered chromosomal regions have been associated with the activation of oncogenes and the inactivation of tumor suppressor genes or defects in mismatch repair (MMR) genes. It is suggested that increased genomic instability is associated with decreased androgen-responsive and progressive behavior of human prostate tumors, but it remains unclear whether this genomic instability is causing the progression of cancer or is the consequence of cancer. Extended studies on hereditary prostate cancer have identified 7 prostate cancer susceptibility loci on several chromosomes, but no specific gene has been confined for a large proportion of susceptibility. In this review we summarize the ongoing molecular genetic events associated with the sporadic and hereditary prostate cancer development and progression.

Citing Articles

Organoboronic acids/esters as effective drug and prodrug candidates in cancer treatments: challenge and hope.

Al-Omari M, Elaarag M, Al-Zoubi R, Al-Qudimat A, Zarour A, Al-Hurani E J Enzyme Inhib Med Chem. 2023; 38(1):2220084.

PMID: 37318308 PMC: 10351539. DOI: 10.1080/14756366.2023.2220084.


Analysis of differentially expressed genes, clinical value and biological pathways in prostate cancer.

He Z, Tang F, Lu Z, Huang Y, Lei H, Li Z Am J Transl Res. 2018; 10(5):1444-1456.

PMID: 29887958 PMC: 5992552.


Genetic alterations in benign prostatic hyperplasia patients.

Mohamed H, Aly M, Hussein T Ger Med Sci. 2017; 15:Doc16.

PMID: 29234244 PMC: 5705825. DOI: 10.3205/000257.


Vitamin K and its analogs: Potential avenues for prostate cancer management.

Dasari S, Ali S, Zheng G, Chen A, Dontaraju V, Bosland M Oncotarget. 2017; 8(34):57782-57799.

PMID: 28915711 PMC: 5593683. DOI: 10.18632/oncotarget.17997.


Long intragenic non-coding RNA lincRNA-p21 suppresses development of human prostate cancer.

Wang X, Ruan Y, Wang X, Zhao W, Jiang Q, Jiang C Cell Prolif. 2016; 50(2).

PMID: 27976428 PMC: 6529152. DOI: 10.1111/cpr.12318.